Pharmacokinetics of ceftriaxone in carbontetrachloride-induced hepatopathic and uranyl nitrate-induced nephropathic goats following single dose intravenous administration.
The pharmacokinetic profile of ceftriaxone was studied in female healthy goats, induced hepatopathic and nephropathic goats after a single intravenous dose at 50 mg kg(-1). Ceftriaxone persisted for 2 h in plasma of hepatopathic goats compared to 1 h of healthy goats, but the kinetic behaviour followed 'one-compartment open model' in both healthy and hepatopathic goats. Mean value of t((1/2))beta (0.32 +/- 0.008 h) was significantly higher in hepatopathic goats compared to healthy goats (0.19 +/- 0.002 h). Ceftriaxone was recovered at 24 h in urine of hepatopathic goats but it could not be detected in urine of healthy goats. However, its metabolite ceftizoxime was present in urine of healthy goats but not in urine of hepatopathic goats. On the other hand ceftriaxone persisted for 2 h in plasma of kidney damaged goats with significant higher concentration compared to healthy goats but kinetic behaviour followed 'one Compartment open model'. Ceftizoxime was identified with an adequate plasma concentration from 8 h to 12 h post dosing in nephropathic goats. Elimination halflife (t(1/2)beta) of Elimination ceftriaxone (0.38 +/- 0.01 h) in nephropathic goats increased significantly compared to healthy goats (0.19 +/- 0.002 h). Ceftriaxone, not the metabolite ceftizoxime was recovered at 24 h and 48 h post dosing in urine of nephropathic goats, while only ceftizoxime not ceftriaxone was detected in urine of healthy goats.
Sar
Tapas Kumar
TK
Department of Pharmacology & Toxicology, West Bengal University of Animal and Fishery Sciences, 37&68, Kshudiram Bose Sarani, Kolkata-37, West Bengal, India.
Mandal
Tapan Kumar
TK
Das
Shymal Kumar
SK
Chakraborty
Animesh Kumar
AK
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002251:Carbon Tetrachloride; D002443:Ceftriaxone / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006041:Goats; D006207:Half-Life; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000188:drug therapy* / Q000662:veterinary; D008107:Liver Diseases / Q000188:drug therapy* / Q000662:veterinary; D023421:Models, Animal; D013997:Time Factors; D014502:Uranyl Nitrate
D000900:Anti-Bacterial Agents; D014502:Uranyl Nitrate; D002443:Ceftriaxone; D002251:Carbon Tetrachloride